Xenetic Biosciences (XBIO) Competitors

Trevena (NASDAQ:TRVN) and Xenetic Biosciences (NASDAQ:XBIO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings, community ranking and analyst recommendations.

Is TRVN or XBIO more profitable?

Trevena has a net margin of 0.00% compared to Trevena's net margin of -162.84%. Trevena's return on equity of -36.43% beat Xenetic Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevena	N/A	-1,018.15%	-98.93%
Xenetic Biosciences	-162.84%	-36.43%	-33.74%

Which has stronger valuation & earnings, TRVN or XBIO?

Xenetic Biosciences has lower revenue, but higher earnings than Trevena. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevena	$3.13M	2.06	-$40.29M	-$3.13	-0.11
Xenetic Biosciences	$2.54M	2.55	-$4.14M	-$2.75	-1.53

Do insiders and institutionals hold more shares of TRVN or XBIO?

13.6% of Trevena shares are owned by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are owned by institutional investors. 2.4% of Trevena shares are owned by insiders. Comparatively, 9.0% of Xenetic Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Does the media favor TRVN or XBIO?

In the previous week, Trevena had 1 more articles in the media than Xenetic Biosciences. MarketBeat recorded 2 mentions for Trevena and 1 mentions for Xenetic Biosciences. Xenetic Biosciences' average media sentiment score of 0.24 beat Trevena's score of -0.63 indicating that Trevena is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trevena	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xenetic Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Does the MarketBeat Community believe in TRVN or XBIO?

Trevena received 441 more outperform votes than Xenetic Biosciences when rated by MarketBeat users. Likewise, 72.27% of users gave Trevena an outperform vote while only 68.24% of users gave Xenetic Biosciences an outperform vote.

Company	Underperform	Outperform
Trevena	Outperform Votes 615 72.27%	Underperform Votes 236 27.73%
Xenetic Biosciences	Outperform Votes 174 68.24%	Underperform Votes 81 31.76%

Do analysts recommend TRVN or XBIO?

Trevena currently has a consensus target price of $9.00, suggesting a potential upside of 2,456.82%. Given Xenetic Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Trevena is more favorable than Xenetic Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevena	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Xenetic Biosciences	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Which has more risk & volatility, TRVN or XBIO?

Trevena has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500. Comparatively, Xenetic Biosciences has a beta of 2.6, suggesting that its stock price is 160% more volatile than the S&P 500.

Summary

Trevena beats Xenetic Biosciences on 10 of the 18 factors compared between the two stocks.